Addex Pharmaceuticals Ltd., of Geneva, named Bruno Bournique head of absorption, distribution, metabolism and excretion and pharmacokinetics.

AEterna Zentaris Inc., of Quebec City, appointed Paul Blake senior vice president and chief medical officer.

Affymax Inc., of Palo Alto, Calif., named Steven Love vice president of finance.

BioVex Inc., of Woburn, Mass., appointed Thaddeus Pullano vice president of quality assurance.

Champions Biotechnology Inc., of Arlington, Va., appointed David Sidransky to its board of directors.

Cytochroma Inc., of Markham, Ontario, named Joel Z. Melnick vice president of clinical and regulatory affairs.

EPIX Pharmaceuticals Inc., of Lexington, Mass., named Margaret Uprichard senior vice president of regulatory affairs and quality.

Interface Biologics Inc., of Toronto, appointed Nicolas Chronos to its advisory board.

MAP Pharmaceuticals Inc., of Mountain View, Calif., named Stephen B. Shrewsbury chief medical officer and Shashidhar Kori vice president of clinical development.

MPI Research, of Mattawan, Mich., named David Serota vice president of toxicology and pathology and Tina Rogers associate director of research.

Ondine Biopharma Corp., of Vancouver, British Columbia, named Timothy Rose chairman of its clinical advisory board.

Protherics plc, of London, named Rolf Soderstrom finance director.

ProtoKinetix Inc., of Vancouver, British Columbia, appointed Ross L. Senior president and CEO.

Seahorse Bioscience, of North Billerica, Mass., appointed Joseph Keegan to its board of directors.

Surface Logix, of Boston, appointed Leland Webster vice president of corporate development.

Uluru Inc., of Addison, Texas, named Tony Vernon to its board of directors.

Vical Inc., of San Diego, appointed Andrew R. de Guttadauro vice president of corporate development.

Zila Inc., of Phoenix, named David R. Bethune executive chairman of its board of directors.